Valoración e intervenciones nutricionales en pacientes en hemodiálisis / Assesment and nutrition intervention in hemodialysis patients

INTRODUCCIÓN: La desnutrición en pacientes dializados es altamente frecuente siendo de etiología multifactorial. OBJETIVO: Realizar diagnóstico de situación y evolución de Parámetros luego de la intervención nutricional. Metas esperadas a los 6 meses: evaluación nutricional en 100% de pacientes; 70% con valoración global subjetiva (VGS) tipo A; 80% con albúmina ≥3.5 g/dl; 70% con ingesta proteica (nPNA) >0.8 g/kg/día. MATERIAL Y MÉTODOS: Se evaluaron pacientes en diálisis con más de 90 días de tratamiento durante marzo y abril (etapa diagnóstica) y noviembre y diciembre de 2016 (evolución de parámetros); registrando datos personales, antropométricos y de laboratorio, anamnesis alimentaria y VGS. Las acciones nutricionales fueron entrevistas a pacientes y familiares, educación a través de charlas grupales e indicación de suplementos hiperproteicos a pacientes seleccionados según apetito, pérdida de peso y albúmina. RESULTADOS: En etapa diagnóstica se evaluaron 35 pacientes; 18 (51%) tenían IMC >23 y <35, 9 (26%) con nPNA >0.8 g/kg/día. Albúmina ≥3.5 g/dl 24 pacientes (69%). VGS tipo A 16 pacientes (46%), tipo B 12 (34%) y tipo C 7 (20%). Se suplementaron 5 pacientes (14%). En etapa posterior se valoraron 28 pacientes; 11 (39%) IMC >23 y <35. nPNA >0.8 g/kg/día 27 pacientes (96%). Albúmina ≥3.5 g/dl 23 pacientes (82%). VGS tipo A 18 (64%), tipo B 9 (32%) y tipo C 1 (4%). 100% de los suplementados lograron las metas esperadas. CONCLUSIÓN: La valoración nutricional periódica, las intervenciones y la suplementación mejoran los objetivos nutricionales a corto plazo de la población en diálisis

INTRODUCTION: Malnutrition, being a condition with a multifactorial etiology, is very frequent in dialysis patients. OBJECTIVE: TO make a diagnosis of the situation and the evolution of parameters following nutrition intervention. Expected goals after six months: nutritional assessment of 100% of patients; 70% with type A subjective global assessment (SGA); 80% with ≥3.5 g/dL albumin levels, and 70% with >0.8 g/kg/day protein intake (nPNA). METHODS: Patients undergoing dialysis for more than 90 days were evaluated during March and April (diagnostic stage) and November and December 2016 (evolution of parameters), recording personal, anthropometric and laboratory data, food history and SGA. The nutritional actions were: interviews to patients and relatives, education through group talks and indication of hyperproteic supplements to patients selected according to appetite, weight loss and albumin. RESULTS: In the diagnostic stage, 35 patients were evaluated; 18 (51%) had BMI > 23 and < 35; 9 (26%) with nPNA > 0.8 g/kg/day. Albumin was ≥3.5 g/dL in 24 patients (69%). Type A SGA in 16 patients(46%); type B in 12 of them (34%) and type C in 7 (20%). Five patients received supplements (14%). In a later stage, 28 patients were evaluated; 11 (39%) with BMI > 23 and < 35. nPNA; > 0.8 g/kg/day in 27 patients (96%). Albumin was ≥3.5 g/dL in 23 patients (82%). Type A SGA in 18 patients (64%); type B in 9 of them (32%) and type C in 1 (4%). 100% of the supplemented subjects achieved the expected goals. CONCLUSION: Periodic nutritional assessment, interventions and supplementation improve the short-term nutritional goals of the dialysis population

Deficiencia de vitamina D en la edad pediátrica. Una oportunidad de prevención / Vitamin D deficiency in childhood: an opportunity for prevention

ResumenLa prevalencia de deficiencia de vitamina D en la población pediátrica ha incrementado en los últimos años y se considera que continúa subdiagnosticada y subtratada. De acuerdo con datos de la Encuesta Nacional de Salud y Nutrición 2006, en México se ha estimado una prevalencia del 16% en niños de 2 a 12 años. La vitamina D desempeña un papel fundamental en la formación y homeostasis del hueso, y consecuentemente en el crecimiento. Su deficiencia se asocia con enfermedades como raquitismo y osteomalacia, y se ha relacionado con otros padecimientos, como obesidad, síndrome metabólico, diabetes, cáncer, infecciones de vías respiratorias y problemas del sistema inmune. En la literatura se han descrito grupos específicos de riesgo para deficiencia de vitamina D en los que el suplemento pudiera ofrecer un beneficio. Actualmente aún hay controversia en definir los niveles séricos de suficiencia, así como la dosis de suplemento. En México, la ingesta diaria sugerida de vitamina D es de 5.6 µg/día (224 UI), que resulta significativamente menor a las recomendaciones en los Estados Unidos y Europa (entre 400 y 1,000 UI). Debido al aumento en la deficiencia de vitamina D en los últimos años y a la falta de consenso con respecto a los niveles de suficiencia de vitamina D (ya que los valores de corte varían de 20 a 30 ng/ml considerados por la asociación de endocrinología), el objetivo de esta revisión fue proporcionar un panorama general del problema en la población pediátrica, así como describir aquellos grupos en riesgo y analizar las recomendaciones vigentes para el suplemento de vitamina D.La deficiencia de vitamina D se ha considerado rara en México, y la falta de evidencia no ha permitido establecer las recomendaciones de ingesta diaria, de acuerdo con el Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Sin embargo, hoy debe reconocerse como un problema de salud, meritorio de atención y acción. Sugerimos que se lleven a cabo estudios prospectivos en nuestro país, donde se establezca la relación entre la deficiencia sérica de vitamina D y la pobre mineralización ósea.

AbstractThe prevalence of vitamin D deficiency in the pediatric population has increased in recent years and continues to be underdiagnosed and undertreated. According to data from the "ENSANUT 2006" (National Health and Nutrition Survey), the prevalence of vitamin D deficiency in Mexico was 16% in children aged 2-12 years. Vitamin D plays a critical role in the formation and bone homeostasis and consequently on growth. Its deficiency is clearly associated with diseases such as rickets and osteomalacia, and it has been linked to other diseases such as obesity, metabolic syndrome, diabetes, cancer, respiratory infections and immune system disease. Specific risk groups have been described in the medical literature for vitamin D deficiency in which supplementation may offer a benefit. Currently, there is still controversy in defining the serum levels of proficiency and dose supplementation. In Mexico, the daily suggested intake of vitamin D is 5.6 µg (224 IU), which is significantly lower than the recommendations in the U.S. and Europe (i.e., between 400 and 1000 IU/day).An increase in vitamin D deficiency has been reported in recent years. There is no consensus regarding the sufficiency levels of vitamin D. Cut-off values vary from 20 to 30 ng/ml. Therefore, the objective of this review was to provide an overview of the problem in the pediatric population and to describe the groups at risk, as well as to analyze the current recommendations for vitamin D supplementation.Vitamin D deficiency was considered rare in Mexico according to the National Institute of Medical Science and Nutrition Salvador Zubirán. Lack of evidence did not help to establish the international recommended daily intake. Currently, vitamin D deficiency must be recognized as a health problem, worthy of attention and action. We suggest that prospective studies are carried out in our country where the relationship between serum vitamin D deficiency and poor bone mineralization will be established.

Correlations of circulating peptide YY and ghrelin with body weight, rate of weight gain, and time required to achieve the recommended daily intake in preterm infants

The objective was to elucidate the relationships between serum concentrations of the gut hormone peptide YY (PYY) and ghrelin and growth development in infants for potential application to the clinical observation index. Serum concentrations of PYY and ghrelin were measured using radioimmunoassay from samples collected at the clinic. For each patient, gestational age, birth weight, time required to return to birth weight, rate of weight gain, time required to achieve recommended daily intake (RDI) standards, time required for full-gastric feeding, duration of hospitalization, and time of administration of total parenteral nutrition were recorded. Serum PYY and ghrelin concentrations were significantly higher in the preterm group (N = 20) than in the full-term group (N = 20; P < 0.01). Within the preterm infant group, the serum concentrations of PYY and ghrelin on postnatal day (PND) 7 (ghrelin = 1485.38 ± 409.24; PYY = 812.37 ± 153.77 ng/L) were significantly higher than on PND 1 (ghrelin = 956.85 ± 223.09; PYY = 545.27 ± 204.51 ng/L) or PND 3 (ghrelin = 1108.44 ± 351.36; PYY = 628.96 ± 235.63 ng/L; P < 0.01). Both serum PYY and ghrelin concentrations were negatively correlated with body weight, and the degree of correlation varied with age. Serum ghrelin concentration correlated negatively with birth weight and positively with the time required to achieve RDI (P < 0.05). In conclusion, serum PYY and ghrelin concentrations reflect a negative energy balance, predict postnatal growth, and enable compensation. Further studies are required to elucidate the precise concentration and roles of PYY and ghrelin in newborns and to determine the usefulness of measuring these hormones in clinical practice.